Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with lowintermediate risk aggressive lymphoma: A final analysis of the multicenter LNH93-2 protocol

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1668-1677

  Morel, Pierre ^a   Munck, Jean Nicolas ^b   Coiffier, Bertrand ^c   Gisselbrecht, Christian ^d   Ranta, Dana ^e   Bosly, Andre ^f   Tilly, Hervé ^g   Quesnel, Bruno ^h   Thyss, Antoine ⁱ   Mounier, Nicolas ^j   Brière, Josette ^k   Molina, Thierry ^l   Reyes, Felix ^m  

^a Centre Hospitalier de LENS   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CHU NANCY BRABOIS   (France)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^g CENTRE HENRI BECQUEREL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l HÔTEL DIEU   (France)

^m HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Aggressive non Hodgkin lymphoma; chemotherapy model; clinical trial; dose escalation

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; IMMUNOBLASTIC LYMPHOMA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; LYMPHOBLASTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; VINDESINE; YOUNG ADULT;

EID: 77956300310     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.504871     Document Type: Article

References (27)

1. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
2. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-1205.
3. Verdonck LF, Notenboom A, de Jong DD, et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007;109:2759-2766.
4. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large- B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
5. Project TN-HsLPC. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
6. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988;1:292-293.
7. Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2000.
8. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284-4289.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
10. Therneau T, Grambsch P. Modeling survival data. Extending the Cox model. New York: Springer; 2000.
11. Gray R. A class of K-sample tests for comparing the cuimulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
12. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dosefinding pilot study. J Clin Oncol 1995;13:2916-2923.
13. Lambertenghi Deliliers G, Butti C, Baldini L, et al. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Haematologica 1995;80:318-324.
14. De Lena M, Maiello E, Lorusso V, et al. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial. Med Oncol Tumor Pharmacother 1989;6:163-169.
15. Aviles A, Guzman R, Delgado S, Nambo MJ, Garcia EL, Diaz-Maqueo JC. Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma. Am J Hematol 1996;52:275-280.
16. Zuckerman KS, Case DC Jr, Gams RA, Prasthofer EF. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen. Blood 1993;82:3564-3573.
17. Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19:545-552.
18. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030.
19. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350: 1287-1295.
20. Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004;22:3099-3103.
21. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
22. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
23. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-251.
24. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265-272.
25. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812.
26. Morel P, Gaulard P, Gisselbrecht C, et al. Autologous stemcell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Ann Oncol 2008;19:560-565.
27. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.